Drug Trial Radar · NCT03237325
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
266
Actual
Start
Dec 4, 2017
Primary completion
Jun 24, 2020
Study completion Jun 24, 2021
Sponsor
- Lead sponsor
- SoligenixIndustry
- Sponsor type
- Industry
- First posted
- Aug 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
Conditions
- Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
- Oral Mucositis
Interventions
SGX942Drug
1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
PlaceboDrug
Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Severe Oral Mucositis (SOM)Time frame: approx. 13 weeks
Locations
53 sites in 5 countries. Site status is shown where the registry gives one.
Arizona Clinical Research Center
Tucson, Arizona
Loma Linda University Health
Loma Linda, California
Pomona Valley Hospital Medical Center
Pomona, California
Cancer Specialists of North Florida
Jacksonville, Florida
Lakes Research
Miami Lakes, Florida
University Cancer & Blood
Athens, Georgia
Augusta University
Augusta, Georgia
Memorial Health
Savannah, Georgia
University of Illinois Cancer Center
Chicago, Illinois
Carle Cancer Center
Urbana, Illinois
Des Moines Oncology Research Association
Des Moines, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Ashland Bellefonte Cancer Center
Ashland, Kentucky
Willis Knighton Cancer Center
Shreveport, Louisiana
Karmanos Cancer Institute
Detroit, Michigan
Minnesota Oncology
Saint Louis Park, Minnesota
University of Missouri-Ellis Fischel Cancer Center
Columbia, Missouri
Great Falls Clinic
Great Falls, Montana
CHI Health St. Francis
Grand Island, Nebraska
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Nevada Cancer Research Foundation
Las Vegas, Nevada
Hackensack Meridian Health
Neptune City, New Jersey
University of Rochester
Rochester, New York
Summa Health Cancer Research
Akron, Ohio
The Christ Hospital
Cincinnati, Ohio
Mercy Clinic Oncology and Hematology
Oklahoma City, Oklahoma
Oklahoma Cancer Specialists
Tulsa, Oklahoma
Charleston Cancer Center
Charleston, South Carolina
Spartanburg Regional-Gibbs Cancer Center
Spartanburg, South Carolina
University of Virginia
Charlottesville, Virginia
Providence Regional Cancer Partnership
Everett, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Centre Hospitalier Jolimont
La Louvière, Belgium
Centre Hospitalier Universitaire de Mons
Mons, Belgium
CFRO Clinique Pasteur
Brest, France
Institut Andrée Dutreix
Dunkirk, France
Clinique Victor Hugo
Le Mans, France
Hôpital de la Croix Rousse
Lyon, France
CROM-Osny
Osny, France
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.